Index additions put fresh attention on Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International (KNSA) has been added to several Russell indices, including the Russell 2000, 2500 and 3000, along with related growth and defensive benchmarks. This shift can reshape how different investors track the stock.

The latest Russell index additions come after a strong run in Kiniksa Pharmaceuticals International's share price. The company has recorded a 30 day share price return of 32.06% and a year to date share price return of 54.17%, while the 1 year total shareholder return of 124.86% and 3 year total shareholder return of about 3.6x suggest investors have already seen substantial gains as attention around the stock has built.

If this kind of momentum has you looking beyond a single biopharma stock, it could be a good moment to scan for other healthcare names linked to AI driven drug development and diagnostics using the 40 healthcare AI stocks

For Kiniksa Pharmaceuticals International, bulls see index inclusion, revenue and net income growth, and a large implied intrinsic discount, while bears focus on a share price near analyst targets. Which side does the valuation math lean toward next?

Most Popular Narrative: 2% Overvalued

Kiniksa Pharmaceuticals International last closed at $64.76, while the most followed narrative anchors fair value at $63.50, leaving a very tight gap between price and modelled worth.

The analysts have a consensus price target of $63.5 for Kiniksa Pharmaceuticals International based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $72.0, and the most bearish reporting a price target of just $57.0.

Want to see what kind of revenue and earnings path could justify that tight pricing range? The narrative instead relies on the prospect of faster growth, rising margins, and a richer future earnings multiple.

Result: Fair Value of $63.50 (OVERVALUED)

However, Kiniksa Pharmaceuticals International still faces key risks, including its heavy reliance on ARCALYST and its exposure to tighter drug pricing or reimbursement pressure that could shift sentiment quickly.

Another View on Kiniksa Pharmaceuticals International’s Valuation

The analysts’ fair value of $63.50 suggests Kiniksa Pharmaceuticals International is only slightly ahead of where the stock trades today. However, the SWS DCF model points in a very different direction, with an estimated future cash flow value of $226.04 and a very large implied undervaluation. Which signal do you put more weight on?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kiniksa Pharmaceuticals International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the split views on Kiniksa Pharmaceuticals International have you unsure, consider acting while sentiment is still forming and weigh the potential upside yourself with the 3 key rewards

Looking for more investment ideas beyond Kiniksa Pharmaceuticals International?

If Kiniksa Pharmaceuticals International has you thinking more broadly about your portfolio, this is a moment to line up your next few ideas before the crowd catches on.

• Spot emerging opportunities early by scanning screener containing 19 high quality undiscovered gems that pair solid fundamentals with lower market attention.
• Strengthen your downside protection by reviewing 72 resilient stocks with low risk scores that score well on resilience and business quality.
• Build a sturdier core for your portfolio by focusing on companies in the solid balance sheet and fundamentals stocks screener (47 results) that can better withstand shocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.